Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11651220 | 0.85 | TSHR (0.64) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4224009 | 0.81 | KDM4E (0.32) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL9111200 | 0.80 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3369383 | 0.80 | ALDH1A1 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL2485099 | 0.80 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL2058172 | 0.78 | USP2 (0.48) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6497418 | 0.78 | TSHR (0.48) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL7548408 | 0.78 | USP2 (0.48) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL18864591 | 0.77 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3370980 | 0.77 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276989-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12264171-B2 | GPR40 agonists | KALLYOPE, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| EP-4110788-A1 | GPR40 AGONISTS | Kallyope, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220289772-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-09-15 | — | — | US | disclosed |
| CN-114450283-A | 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-5580895-A | GASTROINTESTINAL OR CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO SPA (IT) | 1996-12-03 | — | — | US | disclosed |
| EP-0698014-A1 | 3-PHENYLUREIDO-1,5-BENZODIAZEPINE-DIONES USEFUL AS GASTRIN OR CCK ANTAGONISTS | GLAXO S.p.A. (IT) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994025444-A1 | 3-PHENYLUREIDO-1,5-BENZODIAZEPINE-DIONES USEFUL AS GASTRIN OR CCK ANTAGONISTS | GLAXO SPA (IT) | 1994-11-10 | — | — | WO | disclosed |
| EP-0563104-A1 | PESTICIDAL COMPOUNDS | ROUSSEL UCLAF (FR) | 1993-10-06 | — | — | EP | disclosed |
| EP-0558104-A1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993014074-A1 | 1,5-BENZODIAZEPINE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| WO-1992011253-A1 | PESTICIDAL COMPOUNDS | ROUSSEL UCLAF (FR) | 1992-07-09 | — | — | WO | disclosed |
| US-5026874-A | Agricultural insecticides | WELLCOME FOUNDATION LIMITED (GB) | 1991-06-25 | — | — | US | disclosed |
| US-4865641-A | Herbicidal new thiazolyl ether and thioether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-12 | — | — | US | disclosed |
| US-4125544-A | 20/22/23/24-Oxa-7-oxocholesterols and esters thereof | G. D. SEARLE (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264171-B2 | GPR40 agonists | GPR119, GPR65, GLP1R | USP2 3838/4885TSHR 560/4885KDM4E 1099/4885 |
| US-20220289772-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | USP2 3838/4885TSHR 560/4885KDM4E 1099/4885 |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | USP2 2903/4885TSHR 3468/4885KDM4E 1031/4885 |
| US-20250276989-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | USP2 3838/4885TSHR 560/4885KDM4E 1099/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | USP2 2871/4885TSHR 3467/4885KDM4E 1015/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | USP2 2871/4885TSHR 3467/4885KDM4E 1015/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | USP2 2903/4885TSHR 3468/4885KDM4E 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.